Synthes spinal implant recall gets class I notice
This article was originally published in Clinica
The US FDA has given a class I notification to Synthes’ global recall of a component in its Synex expandable vertebral body replacement device. The Swiss firm, which has a facility in West Chester, Pennsylvania, issued a voluntary recall of the Synex II central body components on September 14 after receiving six adverse event reports connected to the technology. According to Synthes, these reports included moderate to severe loss of vertebral body replacement height, due to failure of the central body component, 6-15 months after implantation. These faults could lead to neural injury, increased pain, spinal kyphosis if unrecognised, failure of supplementary fixation and a need for revisional surgery. The Synex technology is a self-locking implant that is designed to restore spinal alignment using rapid and controlled expansion with minimum instrumentation.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals